Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Japanese Pharma Assessing Damage To Plants Amidst Country’s Largest National Disaster; Production Delays Expected

Executive Summary

TOKYO – Following a massive earthquake, tsunami, and potential nuclear disaster, Japan’s leading pharmaceutical companies such as Astellas Pharma Inc. are joining the rest of the country in assessing the damage and taking stock of what needs to be done versus what can be done.

You may also be interested in...



FCPA In The China Framework Warrants Special Attention

The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?

Astellas Regains Japan Losses With Xtandi Expansion

Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.

Astellas Regains Japan Losses With Xtandi Expansion

Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS053232

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel